Kiora Advances Retinal Disease Pipeline with Two Phase 2 Trials Underway

TL;DR

**KPRX is a high-risk, high-reward biotech play; bet on KIO-301's orphan drug potential, but be ready for a long, volatile ride.**

AI Summary

KIORA PHARMACEUTICALS INC (KPRX) is a clinical-stage specialty pharmaceutical company focused on retinal diseases. For the fiscal year ended December 31, 2025, the company reported no revenue, consistent with its clinical-stage status. Key business changes include the ongoing enrollment in the ABACUS-2 Phase 2 clinical trial for KIO-301 in retinitis pigmentosa, following regulatory approval in October 2024. KPRX also initiated enrollment in the KLARITY Phase 2 trial for KIO-104 in retinal inflammation in the second quarter of 2025, with dosing beginning in the third quarter. The company's KIO-301 asset received Orphan Medicinal Product Designation from the European Medicines Agency in July 2024 for non-syndromic, rod-dominant retinal dystrophies, expanded in September 2024 to include syndromic forms like Usher syndrome. Risks include the inherent uncertainties of clinical trials and regulatory approvals, as well as the need for additional financing to fund ongoing development. The strategic outlook involves advancing KIO-301 and KIO-104 through clinical development and exploring strategic partnering for KIO-101.

Why It Matters

Kiora Pharmaceuticals' progress in advancing KIO-301 and KIO-104 into Phase 2 trials is crucial for investors, signaling tangible movement towards potential commercialization in the underserved retinal disease market. Success in these trials could offer new hope for patients with conditions like retinitis pigmentosa and diabetic macular edema, which currently have limited effective treatments. For employees, this clinical progression validates their work and secures future development opportunities. In a competitive landscape dominated by larger pharmaceutical players, Kiora's focus on novel small molecules for orphan and inflammatory retinal diseases positions it as a potential disruptor, offering differentiated therapeutic approaches compared to genetic manipulation or chronic steroid use.

Risk Assessment

Risk Level: high — The risk level is high due to Kiora Pharmaceuticals being a clinical-stage company with no revenue and significant reliance on successful clinical trial outcomes for KIO-301 and KIO-104. The company's aggregate market value of voting and non-voting common equity held by non-affiliates was approximately $10,465,142 as of June 30, 2025, indicating a small market capitalization and potential for high volatility. Furthermore, the company explicitly states in its forward-looking statements that actual results may be materially different due to known and unknown risks, including the timing and success of preclinical studies and clinical trials.

Analyst Insight

Investors should closely monitor the progress and topline data from the ABACUS-2 and KLARITY Phase 2 trials for KIO-301 and KIO-104, respectively. Given the high-risk profile, consider KPRX as a speculative investment with a small allocation, understanding that significant capital raises or partnership deals will be critical for sustained operations and further development.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for the fiscal year ended December 31, 2025, consistent with clinical-stage status.)
• $10.47M — Market Value (Non-Affiliate) (Aggregate market value of common equity held by non-affiliates as of June 30, 2025, indicating a small market capitalization.)
• 3.95M — Shares Outstanding (Total common stock shares outstanding as of March 21, 2026.)
• 36 — ABACUS-2 Trial Patients (Number of patients targeted for the KIO-301 ABACUS-2 Phase 2 clinical trial.)
• 2.4M — Global RP Patients (Estimated number of people worldwide with Retinitis Pigmentosa (RP).)
• 99,593 — U.S. RP Patients (Estimated number of people in the U.S. with Retinitis Pigmentosa (RP).)
• 1M — U.S. GA Patients (Estimated number of patients in the U.S. with Geographic Atrophy (GA), a potential market expansion for KIO-301.)
• 750,000 — U.S. DME Patients (Estimated number of Americans with Diabetic Macular Edema (DME), a target for KIO-104.)
• 0.2M — U.S./UK/EU Posterior Uveitis Cases (Annual cases of posterior non-infectious uveitis in the U.S., UK, and EU, a target for KIO-104.)
• 0.5M+ — U.S. OPRA+ Patients (Estimated number of U.S. patients with Ocular Presentation of Rheumatoid Arthritis (OPRA+), a target for KIO-101.)

Key Players & Entities

• KIORA PHARMACEUTICALS INC (company) — Registrant
• KIO-301 (company) — Lead product candidate for retinitis pigmentosa
• KIO-104 (company) — Product candidate for retinal inflammatory diseases
• Tha Open Innovation (TOI) (company) — Strategic co-development and commercialization partner for KIO-301
• Senju Pharmaceutical Co., Ltd (Senju) (company) — Exclusive option agreement partner
• FDA (regulator) — Granted Orphan Drug Designation for KIO-301
• European Medicines Agency (regulator) — Granted Orphan Medicinal Product Designation for KIO-301
• $10,465,142 (dollar_amount) — Aggregate market value of common equity held by non-affiliates as of June 30, 2025
• 3,950,628 (dollar_amount) — Shares of common stock outstanding at March 21, 2026
• December 31, 2025 (date) — Fiscal year end

Forward-Looking Statements

• KIORA PHARMACEUTICALS INC will continue to file its annual reports in Q1 of the subsequent year. (KIORA PHARMACEUTICALS INC) — high confidence, target: 2027-03-31
• The company's primary business will remain in 'Pharmaceutical Preparations' based on its SIC code. (KIORA PHARMACEUTICALS INC) — high confidence, target: 2026-12-31

FAQ

Risk Factors

• Need for Additional Financing [high — financial]: The company is a clinical-stage biopharmaceutical company with no revenue and significant ongoing research and development expenses. The company will require substantial additional capital to fund its ongoing clinical trials, including the ABACUS-2 and KLARITY trials, and for potential future commercialization. Failure to secure adequate financing could impede or halt development programs.
• Clinical Trial and Regulatory Approval Uncertainty [high — regulatory]: The development of KIO-301 and KIO-104 is subject to inherent uncertainties of clinical trials and regulatory approvals. The success of these trials is not guaranteed, and adverse events or lack of efficacy could lead to delays or termination of development. Regulatory bodies may not approve the products even if clinical trials are successful.
• Dependence on Key Personnel and Third Parties [medium — operational]: The company's success depends on its ability to attract and retain qualified scientific and management personnel. Furthermore, the company relies on third-party contract research organizations (CROs) and manufacturing organizations (CMOs) for the conduct of clinical trials and manufacturing of drug candidates, introducing operational risks.
• Competition in Retinal Disease Market [medium — market]: The market for treatments for retinal diseases is competitive, with existing therapies and numerous companies developing novel treatments. KPRX faces competition from established pharmaceutical companies and emerging biotechs, which could impact market penetration and pricing if its products are approved.
• Orphan Drug Designation Limitations [low — regulatory]: While KIO-301 received Orphan Medicinal Product Designation in Europe for certain retinal dystrophies, this designation provides benefits such as market exclusivity for a period, but does not guarantee regulatory approval or commercial success. The scope of the designation may also be limited.

Industry Context

KIORA PHARMACEUTICALS INC operates in the highly competitive and innovation-driven specialty pharmaceutical sector, specifically focusing on treatments for retinal diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include the increasing prevalence of age-related and genetic eye conditions, driving demand for novel therapies, and advancements in drug delivery mechanisms and genetic therapies. The market is populated by both large pharmaceutical companies with established portfolios and numerous smaller biotech firms like KPRX, all vying for breakthroughs in areas with high unmet medical needs.

Regulatory Implications

The company's development programs for KIO-301 and KIO-104 are heavily dependent on successful clinical trials and subsequent regulatory approvals from agencies like the FDA and EMA. The Orphan Drug Designation for KIO-301 provides potential benefits but does not guarantee market access. Any delays, adverse findings in trials, or failure to meet regulatory standards could significantly impact the company's future prospects and financial viability.

What Investors Should Do

1. Monitor clinical trial progress for KIO-301 (ABACUS-2) and KIO-104 (KLARITY).
2. Evaluate the company's ability to secure additional funding.
3. Assess competitive landscape and potential market penetration for KIO-301 and KIO-104.
4. Review any updates on strategic partnering discussions for KIO-101.

Key Dates

• 2024-10-01: Regulatory approval to initiate Phase 2 clinical trial for KIO-301 (ABACUS-2) — Marks a significant step forward in the clinical development of KIO-301 for retinitis pigmentosa, moving towards efficacy evaluation.
• 2024-07-01: KIO-301 received Orphan Medicinal Product Designation from EMA — Provides potential market exclusivity in Europe and signifies regulatory recognition of KIO-301's potential for rare diseases.
• 2025-05-01: Data from KIO-104 Phase 1b/2a study presented at ARVO — Showcased positive preclinical data in Proliferative Vitreoretinopathy models, potentially expanding the therapeutic applications of KIO-104.
• 2025-05-01: Approval to start enrolling patients for KIO-104 — Indicates progress in advancing KIO-104 for retinal inflammatory diseases, moving towards further clinical evaluation.
• 2025-04-01: KLARITY Phase 2 trial for KIO-104 initiated enrollment — Commencement of a key clinical trial for KIO-104, targeting retinal inflammation indications like DME and uveitis.
• 2025-07-01: Dosing began in KLARITY Phase 2 trial for KIO-104 — Active patient treatment in the KLARITY trial, generating data on KIO-104's efficacy and safety in retinal inflammation.

Glossary

Retinitis Pigmentosa (RP)

A group of inherited eye diseases that affect the retina's ability to respond to light, leading to progressive vision loss. (Primary indication for KIO-301, representing a significant patient population for the company's lead asset.)

Photoswitch

A molecule designed to restore light sensitivity to photoreceptor cells that have lost their function. (Describes the mechanism of action for KIO-301, highlighting its novel approach to vision restoration.)

Dihydroorotate Dehydrogenase (DHODH)

An enzyme involved in pyrimidine synthesis, which plays a role in immune cell proliferation. Inhibiting DHODH can suppress T-cell activity. (The target of KIO-104, explaining its mechanism for treating inflammatory eye diseases.)

Diabetic Macular Edema (DME)

Swelling in the macula, the central part of the retina, caused by complications from diabetes, leading to vision loss. (One of the target indications for KIO-104, representing a substantial market opportunity.)

Posterior Non-Infectious Uveitis

Inflammation of the posterior part of the eye, not caused by infection, often involving T-cells. (Another key indication for KIO-104, addressing a significant unmet need in ophthalmology.)

Orphan Medicinal Product Designation

A status granted by regulatory authorities (like the EMA or FDA) to drugs intended to treat rare diseases, offering incentives such as market exclusivity. (KIO-301 has received this designation in Europe, potentially providing a competitive advantage and extended market protection.)

Intravitreal Delivery

Administration of a drug directly into the vitreous humor of the eye. (The method of delivery for KIO-104, designed for localized treatment and potentially reduced systemic side effects.)

Year-Over-Year Comparison

As a clinical-stage company, KPRX reported $0 revenue in the current fiscal year, consistent with its prior filings. The primary focus remains on advancing its pipeline assets, KIO-301 and KIO-104, through clinical trials. Key developments include the ongoing enrollment in the ABACUS-2 Phase 2 trial for KIO-301 and the initiation of the KLARITY Phase 2 trial for KIO-104, indicating progress in development activities. New risks related to the specific progression and outcomes of these trials, alongside the perpetual need for financing, are likely to be emphasized compared to the previous filing.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value KPRX The NASDAQ Capital Marke
• $1.25 million — we received a nonrefundable payment of $1.25 million. In the future, if the option is exerci
• $109.5 million — ll be eligible to receive an additional $109.5 million in milestone payments plus tiered, mid
• $16 million — ntents received an upfront payment of $16 million and will be eligible to receive aggrega
• $285 million — commercial milestone payments of up to $285 million and tiered commercial royalties up to t

Filing Documents

• kprx-20251231.htm (10-K) — 1857KB
• ex141-kioraxcodexofxethics.htm (EX-14.1) — 81KB
• ex231-20251231xkprx.htm (EX-23.1) — 3KB
• ex311-20251231xkprx.htm (EX-31.1) — 8KB
• ex312-20251231xkprx.htm (EX-31.2) — 8KB
• ex321-20251231xkprx.htm (EX-32.1) — 4KB
• ex322-20251231xkprx.htm (EX-32.2) — 4KB
• hwlogoa.jpg (GRAPHIC) — 40KB
• kprx-20251231_g1.jpg (GRAPHIC) — 341KB
• kprx-20251231_g2.jpg (GRAPHIC) — 140KB
• 0001372514-26-000024.txt ( ) — 11697KB
• kprx-20251231.xsd (EX-101.SCH) — 75KB
• kprx-20251231_cal.xml (EX-101.CAL) — 127KB
• kprx-20251231_def.xml (EX-101.DEF) — 362KB
• kprx-20251231_lab.xml (EX-101.LAB) — 939KB
• kprx-20251231_pre.xml (EX-101.PRE) — 658KB
• kprx-20251231_htm.xml (XML) — 1437KB

Forward-Looking Statements

Forward-Looking Statements 2 PART I Item 1.

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 21 Item 1B. Unresolved Staff Comments 50 Item 1C. Cybersecurity 50 Item 2.

Properties

Properties 52 Item 3.

Legal Proceedings

Legal Proceedings 52 Item 4. Mine Safety Disclosures 52 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 53 Item 6. Reserved 53 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 53 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 66 Item 8. Consolidated Financial Statements and Supplementary Data 66 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 66 Item 9A.

Controls and Procedures

Controls and Procedures 67 Item 9B. Other Information 68 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 68 PART III Item 10. Directors, Executive Officers and Corporate Governance 69 Item 11.

Executive Compensation

Executive Compensation 69 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 69 Item 13. Certain Relationships and Related Transactions, and Director Independence 69 Item 14. Principal Accounting Fees and Services 69 PART IV Item 15. Exhibits, Consolidated Financial Statement Schedules 70 Index to Consolidated Financial Statements F- 1 Item 16. Form 10-K Summary 75

Signatures

Signatures 92 1 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this "Annual Report on Form 10-K", this "Annual Report" or this "Form 10-K") contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The forward-looking statements are principally, but not exclusively, contained in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management's confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "goals," "sees," "estimates," "projects," "predicts," "intends," "think," "potential," "objectives," "optimistic," "strategy," and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the timing and success of preclinical studies and clinical trials conducted by us and our development partners; the ability to obtain and maintain regulatory approval of our product candidates, and the labeling for any appr

BUSINESS

ITEM 1. BUSINESS Overview We are a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases. We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP"). KIO-301 is a potential vision-restoring small molecule that acts as a "photoswitch" specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP. We completed a Phase 1b clinical trial in September 2023 and presented topline results in November 2023 at the American Academy of Ophthalmology Annual Meeting. The full data package triggered multiple discussions with various potential pharmaceutical partners. After assessing available options, in January 2024, we partnered with Tha Open Innovation ("TOI"), a sister company of Laboratories Tha. In October 2024, we received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 in patients with retinitis pigmentosa. The ABACUS-2 trial is a 36 patient, multicenter, double-masked, randomized, controlled, multiple dose study enrolling patients with ultra-low vision or no light perception regardless of their underlying gene mutation associated with retinitis pigmentosa. Enrollment in the ABACUS-2 trial is currently ongoing. As KIO-301 and its sister molecules are ion channel modulators, the potential to treat other neurological diseases exists. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. ("Bayon") transaction which closed October 21, 2021. We are also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a T cell-mediated, intraocular inflammatory disease. KIO-104 is a novel and potent, non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase ("DHODH") form

View Full Filing

View this 10-K filing on SEC EDGAR